Search
ASCO 2026: Immuneering presented an update of the P2 trial of its deep cyclic inhibitor of MEK in 1L pancreatic cancer at ASCO. CEO Ben Zeskind argues why competitor data should not overshadow this
He describes the data, which showed a 17.3 months median OS in 55 patients vs. 8.5 months for SoC, and descrbies why he believes the therapy has an ideal profile for first line patients. A phase three study is already active and accruing patients.
Jun 1
Immuneering's CEO walks us through the company's MEK data in pancreatic cancer, and explains the science behind 'deep cyclic inhibition'
Ben Zeskind describes the company's 9 month follow-up for atebimetinib + mGnP, which showed 86% overall survival and 53% progression free...
Oct 8, 2025
.png){kind=logo}